Skin Diseases, Bacterial
Welcome,         Profile    Billing    Logout  
 30 Companies   20 Products   20 Products   12 Mechanisms of Action   0 Trials   103 News 


123»
  • ||||||||||  Trial completion, Enrollment change:  Analysis of Lyme Disease Lesions (clinicaltrials.gov) -  Dec 3, 2018   
    P=N/A,  N=27, Completed, 
    Recruiting --> Completed | N=60 --> 27
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess (clinicaltrials.gov) -  Aug 29, 2018   
    P1/2,  N=6, Completed, 
    Recruiting --> Completed | N=60 --> 27 Not yet recruiting --> Completed | N=100 --> 6 | Trial completion date: Apr 2019 --> Aug 2017 | Trial primary completion date: Oct 2018 --> Aug 2017
  • ||||||||||  Trial completion, Trial primary completion date:  Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs). (clinicaltrials.gov) -  Apr 23, 2018   
    P=N/A,  N=409, Completed, 
    Not yet recruiting --> Completed | N=100 --> 6 | Trial completion date: Apr 2019 --> Aug 2017 | Trial primary completion date: Oct 2018 --> Aug 2017 Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jun 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  Analysis of Lyme Disease Lesions (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=60, Recruiting, 
    Recruiting --> Completed | Trial primary completion date: Oct 2017 --> Jun 2017 Phase classification: P=N/A --> P
  • ||||||||||  mupirocin / Generic mfg.
    Trial completion, Trial completion date:  HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) -  Feb 28, 2018   
    P=N/A,  N=671, Completed, 
    Phase classification: P=N/A --> P Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Nov 2017
  • ||||||||||  flucloxacillin sodium / Generic mfg.
    Enrollment change, Trial termination:  DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) -  Oct 9, 2017   
    P4,  N=151, Terminated, 
    Enrolling by invitation --> Completed | Trial completion date: Dec 2017 --> Nov 2017 N=316 --> 151 | Active, not recruiting --> Terminated; Budget exceeded
  • ||||||||||  Trial primary completion date:  Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs). (clinicaltrials.gov) -  Aug 21, 2017   
    P=N/A,  N=500, Recruiting, 
    N=316 --> 151 | Active, not recruiting --> Terminated; Budget exceeded Trial primary completion date: Jun 2017 --> Oct 2017
  • ||||||||||  flucloxacillin sodium / Generic mfg.
    Enrollment closed, Trial primary completion date:  DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) -  Aug 16, 2017   
    P4,  N=316, Active, not recruiting, 
    Trial primary completion date: Jun 2017 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Jul 2017
  • ||||||||||  prednisone / Generic mfg.
    Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date:  The Use of Oral Steroids in the Treatment of Cellulitis (clinicaltrials.gov) -  Jul 25, 2017   
    P2,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2018 --> Jul 2017 N=35 --> 0 | Initiation date: Sep 2009 --> Jan 2010 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2010 --> Aug 2010
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
    Trial withdrawal:  Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) -  Apr 7, 2017   
    P1/2,  N=0, Withdrawn, 
    N=35 --> 0 | Initiation date: Sep 2009 --> Jan 2010 | Not yet recruiting --> Withdrawn | Trial primary completion date: Mar 2010 --> Aug 2010 Enrolling by invitation --> Withdrawn
  • ||||||||||  flucloxacillin sodium / Generic mfg.
    Trial primary completion date:  DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) -  Jan 24, 2017   
    P4,  N=316, Recruiting, 
    Enrolling by invitation --> Withdrawn Trial primary completion date: Apr 2017 --> Jan 2018
  • ||||||||||  Kepivance (palifermin) / SOBI, Amgen
    Trial termination:  Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis (clinicaltrials.gov) -  Aug 11, 2016   
    P1/2,  N=1, Terminated, 
    Active, not recruiting --> Completed Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time.
  • ||||||||||  mupirocin / Generic mfg.
    Trial primary completion date:  HOME2DS: Individualized vs. Household MRSA Decolonization (clinicaltrials.gov) -  May 3, 2016   
    P=N/A,  N=600, Enrolling by invitation, 
    Recruiting --> Terminated; Low enrollment numbers precluded completion of the study during a reasonable amount of time. Trial primary completion date: Jun 2016 --> Jan 2017
  • ||||||||||  doxycycline / Generic mfg.
    Trial completion, Trial primary completion date:  Doxycycline in Therapy of Erythema Migrans (clinicaltrials.gov) -  Mar 24, 2016   
    P=N/A,  N=400, Completed, 
    Trial primary completion date: Jun 2016 --> Jan 2017 Recruiting --> Completed | Trial primary completion date: May 2013 --> Oct 2014
  • ||||||||||  Enbrel (etanercept) / Pfizer, Amgen
    Trial completion:  Etanercept for Treatment of Hidradenitis (clinicaltrials.gov) -  Feb 27, 2016   
    P2,  N=15, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed
  • ||||||||||  Altabax (retapamulin) / GSK, Almirall
    Trial completion, Enrollment change, Trial primary completion date:  Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection (clinicaltrials.gov) -  Feb 17, 2016   
    P4,  N=38, Completed, 
    Recruiting --> Completed | N=114 --> 169 Recruiting --> Completed | N=75 --> 38 | Trial primary completion date: Apr 2012 --> Nov 2012
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change:  Analysis of Lyme Disease Lesions (clinicaltrials.gov) -  Dec 23, 2015   
    P=N/A,  N=60, Recruiting, 
    Trial primary completion date: Mar 2016 --> Sep 2016 N=40 --> 60
  • ||||||||||  Biomarker, Trial primary completion date, IO biomarker:  BIONEC: Biomarkers in Patients With Flesh-eating Bacterial Infections (clinicaltrials.gov) -  Oct 22, 2015   
    P=N/A,  N=114, Recruiting, 
    Recruiting --> Withdrawn | Trial primary completion date: Jul 2015 --> Jan 2015 Trial primary completion date: Jul 2015 --> Feb 2016
  • ||||||||||  flucloxacillin sodium / Generic mfg.
    Enrollment change:  DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) -  Aug 11, 2015   
    P4,  N=316, Recruiting, 
    Trial primary completion date: Jul 2015 --> Feb 2016 N=396 --> 316
  • ||||||||||  Trial completion, Enrollment change:  Culture Media for Borrelia Burgdorferi Sensu Lato (clinicaltrials.gov) -  Jun 30, 2015   
    P=N/A,  N=235, Completed, 
    Trial primary completion date: Jul 2015 --> Mar 2016 Recruiting --> Completed | N=150 --> 235
  • ||||||||||  Kineret (anakinra) / SOBI
    Trial completion, Trial primary completion date:  Anakinra in Hidradenitis Suppurativa (clinicaltrials.gov) -  May 27, 2015   
    P2,  N=20, Completed, 
    Recruiting --> Completed | N=150 --> 235 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Feb 2014
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
    Enrollment open:  Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) -  Nov 4, 2014   
    P1/2,  N=4, Enrolling by invitation, 
    Active, not recruiting --> Completed | N=100 --> 224 Not yet recruiting --> Enrolling by invitation
  • ||||||||||  flucloxacillin sodium / Generic mfg.
    Enrollment open, Trial initiation date:  DANCE: Duration of ANtibiotic Therapy for CEllulitis (clinicaltrials.gov) -  Aug 4, 2014   
    P4,  N=396, Recruiting, 
    N=224 --> 100 Not yet recruiting --> Recruiting | Initiation date: Feb 2014 --> Aug 2014